177 related articles for article (PubMed ID: 8577045)
1. [Disorders of glycoprotein degradation].
Yoshida K; Yanagisawa N
Nihon Rinsho; 1995 Dec; 53(12):2973-81. PubMed ID: 8577045
[TBL] [Abstract][Full Text] [Related]
2. Disorders of glycoprotein degradation.
Cantz M; Ulrich-Bott B
J Inherit Metab Dis; 1990; 13(4):523-37. PubMed ID: 2122119
[TBL] [Abstract][Full Text] [Related]
3. Lysosomal metabolism of glycoproteins.
Winchester B
Glycobiology; 2005 Jun; 15(6):1R-15R. PubMed ID: 15647514
[TBL] [Abstract][Full Text] [Related]
4. [Metabolic pathway of the degradation of macromolecules by lysosomal enzymes].
Arai K; Ohkuma S
Nihon Rinsho; 1995 Dec; 53(12):2904-10. PubMed ID: 8577033
[TBL] [Abstract][Full Text] [Related]
5. A novel aspartylglucosaminuria mutation affects translocation of aspartylglucosaminidase.
Saarela J; von Schantz C; Peltonen L; Jalanko A
Hum Mutat; 2004 Oct; 24(4):350-1. PubMed ID: 15365992
[TBL] [Abstract][Full Text] [Related]
6. Amlexanox provides a potential therapy for nonsense mutations in the lysosomal storage disorder Aspartylglucosaminuria.
Banning A; Schiff M; Tikkanen R
Biochim Biophys Acta Mol Basis Dis; 2018 Mar; 1864(3):668-675. PubMed ID: 29247835
[TBL] [Abstract][Full Text] [Related]
7. [Molecular genetics of aspartylglucosaminuria].
Palotie L; Ikonen E; Syvänen AC; Halila R; Enomaa N; Heiskanen T; Grön K; Aula P
Duodecim; 1991; 107(23-24):1916-25. PubMed ID: 1366100
[No Abstract] [Full Text] [Related]
8. Adenovirus-mediated gene transfer results in decreased lysosomal storage in brain and total correction in liver of aspartylglucosaminuria (AGU) mouse.
Peltola M; Kyttälä A; Heinonen O; Rapola J; Paunio T; Revah F; Peltonen L; Jalanko A
Gene Ther; 1998 Oct; 5(10):1314-21. PubMed ID: 9930336
[TBL] [Abstract][Full Text] [Related]
9. [Thin-layer chromatography of urine oligosaccharides in diagnosis of some lysosomal storage disorders].
Lugowska A; Tylki-Szymańska A; Sawnor-Korszyńska D
Pediatr Pol; 1995 Oct; 70(10):847-55. PubMed ID: 8649932
[TBL] [Abstract][Full Text] [Related]
10. Correction of deficient enzyme activity in a lysosomal storage disease, aspartylglucosaminuria, by enzyme replacement and retroviral gene transfer.
Enomaa N; Danos O; Peltonen L; Jalanko A
Hum Gene Ther; 1995 Jun; 6(6):723-31. PubMed ID: 7548272
[TBL] [Abstract][Full Text] [Related]
11. Toward understanding the neuronal pathogenesis of aspartylglucosaminuria: expression of aspartylglucosaminidase in brain during development.
Uusitalo A; Tenhunen K; Heinonen O; Hiltunen JO; Saarma M; Haltia M; Jalanko A; Peltonen L
Mol Genet Metab; 1999 Aug; 67(4):294-307. PubMed ID: 10444340
[TBL] [Abstract][Full Text] [Related]
12. Use of nonviral promoters in adenovirus-mediated gene therapy: reduction of lysosomal storage in the aspartylglucosaminuria mouse.
Virta S; Rapola J; Jalanko A; Laine M
J Gene Med; 2006 Jun; 8(6):699-706. PubMed ID: 16518877
[TBL] [Abstract][Full Text] [Related]
13. Mutations causing aspartylglucosaminuria (AGU): a lysosomal accumulation disease.
Ikonen E; Peltonen L
Hum Mutat; 1992; 1(5):361-5. PubMed ID: 1301945
[TBL] [Abstract][Full Text] [Related]
14. Glycoprotein lysosomal storage disorders: alpha- and beta-mannosidosis, fucosidosis and alpha-N-acetylgalactosaminidase deficiency.
Michalski JC; Klein A
Biochim Biophys Acta; 1999 Oct; 1455(2-3):69-84. PubMed ID: 10571005
[TBL] [Abstract][Full Text] [Related]
15. Correction of peripheral lysosomal accumulation in mice with aspartylglucosaminuria by bone marrow transplantation.
Laine M; Richter J; Fahlman C; Rapola J; Renlund M; Peltonen L; Karlsson S; Jalanko A
Exp Hematol; 1999 Sep; 27(9):1467-74. PubMed ID: 10480438
[TBL] [Abstract][Full Text] [Related]
16. [Aspartylglucosaminuria].
Yamaguchi S
Ryoikibetsu Shokogun Shirizu; 1998; (19 Pt 2):466-8. PubMed ID: 9645112
[No Abstract] [Full Text] [Related]
17. [Lysosomal glycosidases and glycoproteinoses].
Montreuil J
C R Seances Soc Biol Fil; 1981; 175(5):694-707. PubMed ID: 6456795
[TBL] [Abstract][Full Text] [Related]
18. Aspartylglycosaminuria: a review.
Arvio M; Mononen I
Orphanet J Rare Dis; 2016 Dec; 11(1):162. PubMed ID: 27906067
[TBL] [Abstract][Full Text] [Related]
19. Validation of Aspartylglucosaminidase Activity Assay for Human Serum Samples: Establishment of a Biomarker for Diagnostics and Clinical Studies.
Banning A; Laine M; Tikkanen R
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982794
[TBL] [Abstract][Full Text] [Related]
20. Identification of a novel mutation causing aspartylglucosaminuria reveals a mutation hotspot region in the aspartylglucosaminidase gene.
Isoniemi A; Hietala M; Aula P; Jalanko A; Peltonen L
Hum Mutat; 1995; 5(4):318-26. PubMed ID: 7627186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
